GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (LTS:0OIR) » Definitions » COGS-to-Revenue

Alk-Abello AS (LTS:0OIR) COGS-to-Revenue : 0.37 (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Alk-Abello AS COGS-to-Revenue?

Alk-Abello AS's Cost of Goods Sold for the three months ended in Jun. 2024 was kr507 Mil. Its Revenue for the three months ended in Jun. 2024 was kr1,374 Mil.

Alk-Abello AS's COGS to Revenue for the three months ended in Jun. 2024 was 0.37.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Alk-Abello AS's Gross Margin % for the three months ended in Jun. 2024 was 63.10%.


Alk-Abello AS COGS-to-Revenue Historical Data

The historical data trend for Alk-Abello AS's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS COGS-to-Revenue Chart

Alk-Abello AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 0.42 0.39 0.38 0.37

Alk-Abello AS Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.38 0.37 0.34 0.37

Alk-Abello AS COGS-to-Revenue Calculation

Alk-Abello AS's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1789 / 4824
=0.37

Alk-Abello AS's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=507 / 1374
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alk-Abello AS  (LTS:0OIR) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Alk-Abello AS's Gross Margin % for the three months ended in Jun. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 507 / 1374
=63.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Alk-Abello AS COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello AS Business Description

Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.

Alk-Abello AS Headlines

No Headlines